Treatment of Blepharitis With Povidone-Iodine 1%

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

One hundred blepharitis patients will be recruited. Each patient will treat one eye once daily with 1% PVI for 30 days by scrubbing the eyelid margin with the solution. The fellow eye will serve as the control and be given the standard treatment (commercial eye wipes). Before treatment initiation, various ocular surface variables will be assessed, such as dry eye grading, subjective discomfort scales, ocular surface questionnaire, and other clinical signs. After 30 days, an identical evaluation will be performed.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shaare Zedek Medical Center
• Treatments: Povidone; Povidone-Iodine

Criteria

Inclusion Criteria:

• Age 18 or older.

• Anterior or mixed (anterior + posterior) blepharitis.

• Similar clinical condition of both eyes.

Exclusion Criteria:

• Any ocular surface disease other than blepharitis.

• Known allergy to iodine.

• Eye surgery in the last 6 months.

• Ocular trauma in the last 6 months.

• Use of contact lenses in the last 6 months.

• Pregnancy or lactation.

• Daily use of makeup on lashes.

• Any ocular or systemic medication that might affect the ocular microbiota (antibiotics, immunosuppressants, steroids).